Santella R M, Yang X Y, DeLeo V A, Gasparro F P
Comprehensive Cancer Center, School of Public Health, Columbia University, New York, NY.
IARC Sci Publ. 1988(89):333-40.
8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL). We have developed monoclonal antibodies which specifically recognize 8-MOP-modified DNA and do not cross-react with unmodified DNA or free 8-MOP. Highly sensitive, competitive enzyme-linked immunosorbent assays (ELISA) have been developed with both colour and fluorescence endpoint detection for quantification of DNA adducts in biological samples. In addition, immunofluorescence and flow cytometric techniques have been developed to visualize adducts in tissues and cells. These techniques have been validated in keratinocytes treated in culture and in animals treated in vivo with 8-MOP and ultraviolet A (UVA) light. Adduct levels have also been monitored in skin biopsies and lymphocytes of patients with psoriasis and lymphoma.
8-甲氧基补骨脂素（8-MOP）是一种临床上用于治疗银屑病和皮肤T细胞淋巴瘤（CTCL）的光活化药物。我们已经开发出特异性识别8-MOP修饰DNA且不与未修饰DNA或游离8-MOP发生交叉反应的单克隆抗体。已经开发出高灵敏度的竞争性酶联免疫吸附测定（ELISA），具有颜色和荧光终点检测，用于定量生物样品中的DNA加合物。此外，还开发了免疫荧光和流式细胞术技术，以可视化组织和细胞中的加合物。这些技术已在培养中处理的角质形成细胞以及用8-MOP和紫外线A（UVA）光进行体内处理的动物中得到验证。还对银屑病和淋巴瘤患者的皮肤活检组织和淋巴细胞中的加合物水平进行了监测。
